Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04319783




Registration number
NCT04319783
Ethics application status
Date submitted
9/03/2020
Date registered
24/03/2020
Date last updated
28/02/2024

Titles & IDs
Public title
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Scientific title
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Secondary ID [1] 0 0
U1111-1242-9233
Secondary ID [2] 0 0
TROG 19.06
Universal Trial Number (UTN)
Trial acronym
DECREASE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced Prostate Carcinoma 0 0
Cancer of Prostate 0 0
PSA 0 0
Castrate Resistant Prostate Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Darolutamide
Treatment: Other - Radiotherapy

Experimental: Darolutamide - Darolutimide 600mg BD

Experimental: Local consolidation Radiotherapy + Darolutamide - Darolutimide 600mg BD + local consolidative radiotherapy, with a biological equivalent dose of 30Gy/10fx or greater if delivered with SABR. SABR is the preferred treatment approach, however conventional radiotherapy is acceptable. To up to 5 sites of disease


Treatment: Drugs: Darolutamide
Darolutamide alone

Treatment: Other: Radiotherapy
Darolutamide + Consolidation Radiotherapy
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Undetectable PSA at 12 months
Timepoint [1] 0 0
12 months
Secondary outcome [1] 0 0
Radiological progression free survival
Timepoint [1] 0 0
36 months
Secondary outcome [2] 0 0
Distribution of disease on baseline PSMA-PET/CT imaging
Timepoint [2] 0 0
36 months
Secondary outcome [3] 0 0
Biochemical progression free survival
Timepoint [3] 0 0
36 months
Secondary outcome [4] 0 0
Treatment related adverse event
Timepoint [4] 0 0
36 months
Secondary outcome [5] 0 0
Overall survival
Timepoint [5] 0 0
36 months
Secondary outcome [6] 0 0
Patterns of disease on PSMA PET/CT after 12 weeks of commencing Darolutamide, and at time of disease progression
Timepoint [6] 0 0
3 months

Eligibility
Key inclusion criteria
- = 18 years of age and provided written Informed Consent

- Histologically or cytologically confirmed adenocarcinoma of the prostate without
neuroendocrine differentiation or small cell features

- Castration-resistant prostate cancer, defined as at least 2 consecutive PSA rises
obtained at least 1 week apart in the setting of castrate testosterone levels

- Castrate level of serum testosterone (<1.7 nmol/l [50 ng/dl]) on gonadotrophin -
releasing hormone (GnRH) agonist or antagonist therapy or after bilateral orchiectomy

- A baseline PSA level of at least 1ng per millilitre and a PSA doubling time of 10
months or less

- Adequate bone marrow reserve and organ function Eastern Cooperative Oncology Group
(ECOG) performance status of 0 or 1

- At least 1 site of PSMA-avid disease on PSMA-PET/CT imaging in any of the following
regions; At least 1 site of PSMA-avid disease on PSMA-PET/CT imaging in any of the
following regions:

- Local recurrence within the prostate gland or prostate bed

- Regional lymph node disease (below the aortic bifurcation)

- Extra-pelvic lymph node, bone or soft tissue metastatic disease
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with detectable metastases or a history of metastatic disease on conventional
imaging

- Prior treatment with second-generation androgen receptor (AR) antagonists, CYP17
enzyme inhibitors or oral ketoconazole

- Use of oestrogens or 5-a reductase inhibitors or anti-androgens within 28 days before
randomisation

- Use of systemic corticosteroid with a dose greater than the equivalent 10 mg of
prednisone/day within 28 days before randomisation

- Radiotherapy within 12 weeks prior to randomisation

- Initiation of treatment with an osteoclast-targeted therapy to prevent
skeletal-related events within 12 weeks before randomisation

- Any of the following within 6 months before randomisation: stroke, myocardial
infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft;
congestive heart failure New York Heart Association (NYHA) Class III or IV

- Uncontrolled hypertension

- Prior malignancy

- Gastrointestinal disorder or procedure that expects to interfere significantly with
the absorption of study treatment

- Unable to swallow study medications and comply with study requirements

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/06/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2026
Actual
Sample size
Target
87
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
St Vincent's Hospital - Darlinghurst
Recruitment hospital [2] 0 0
GenesisCare Hurstville - Hurstville
Recruitment hospital [3] 0 0
GenesisCare North Shore - Saint Leonards
Recruitment hospital [4] 0 0
Calvary Mater Newcastle - Waratah
Recruitment hospital [5] 0 0
Townsville University Hospital - Douglas
Recruitment hospital [6] 0 0
Royal Brisbane and Women's Hospital - Herston
Recruitment hospital [7] 0 0
Princess Alexandra Hospital (ROPART) - Raymond Terrace
Recruitment hospital [8] 0 0
Princess Alexandra Hospital (ROPAIR) - Woolloongabba
Recruitment hospital [9] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [10] 0 0
Royal Hobart Hospital - Hobart
Recruitment hospital [11] 0 0
Peter MacCallum Cancer Centre, Bendigo - Bendigo
Recruitment hospital [12] 0 0
Peter MacCallum Cancer Centre, Box Hill - Box Hill
Recruitment hospital [13] 0 0
Peter MacCallum Cancer Centre, Parkville - Melbourne
Recruitment hospital [14] 0 0
Icon Cancer Centre Epworth - Richmond
Recruitment hospital [15] 0 0
Western Health - St Albans
Recruitment hospital [16] 0 0
GenesisCare Fiona Stanley Hospital - Murdoch
Recruitment postcode(s) [1] 0 0
2101 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2220 - Hurstville
Recruitment postcode(s) [3] 0 0
2065 - Saint Leonards
Recruitment postcode(s) [4] 0 0
2298 - Waratah
Recruitment postcode(s) [5] 0 0
4814 - Douglas
Recruitment postcode(s) [6] 0 0
4006 - Herston
Recruitment postcode(s) [7] 0 0
4101 - Raymond Terrace
Recruitment postcode(s) [8] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [9] 0 0
5000 - Adelaide
Recruitment postcode(s) [10] 0 0
7000 - Hobart
Recruitment postcode(s) [11] 0 0
3550 - Bendigo
Recruitment postcode(s) [12] 0 0
3128 - Box Hill
Recruitment postcode(s) [13] 0 0
3002 - Melbourne
Recruitment postcode(s) [14] 0 0
3121 - Richmond
Recruitment postcode(s) [15] 0 0
3021 - St Albans
Recruitment postcode(s) [16] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
Singapore
State/province [1] 0 0
Singapore

Funding & Sponsors
Primary sponsor type
Other
Name
Trans Tasman Radiation Oncology Group
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Bayer
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Peter MacCallum Cancer Centre, Australia
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate
resistant prostate cancer when using conventional imaging. However, it is estimated that >90%
of patients have disease apparent when using PSMA PET. This study investigates the use of
local consolidation radiotherapy in this cohort of men.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04319783
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Shankar Siva
Address 0 0
Peter MacCallum Cancer Centre, Australia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Rebecca Montgomery
Address 0 0
Country 0 0
Phone 0 0
+61 2 4014 3910
Fax 0 0
Email 0 0
decrease@trog.com.au
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04319783